微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2026-03-31 | 62.39% | 2.26% | 16.6% | 48/157 | 50.55% | 泽璟制药 | 94.64% | 行业排名> |
| 2025-12-31 | 53.51% | -1.33% | -6% | 67/157 | 50.61% | 海创药业 | 99.82% | 行业排名> |
| 2025-09-30 | 56.93% | -1.75% | -2.11% | 59/157 | -2.2% | 海创药业 | 98.62% | 行业排名> |
| 2025-06-30 | 58.16% | -2.76% | -4.68% | 57/157 | 14.83% | 海创药业 | 99.57% | 行业排名> |
| 2025-03-31 | 61.01% | 4.68% | 12.5% | 45/157 | 31.96% | 海创药业 | 99.52% | 行业排名> |
| 2024-12-31 | 54.23% | -1.48% | -6.4% | 71/157 | 51.88% | 艾力斯 | 96.74% | 行业排名> |
| 2024-09-30 | 57.94% | 0.46% | -3.12% | 59/157 | 22.51% | 首药控股 | 98.96% | 行业排名> |
| 2024-06-30 | 59.8% | 3.11% | 2.61% | 53/157 | 33.12% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-03-31 | 58.29% | -1.03% | 5.88% | 55/157 | 51.76% | 百利天恒 | 97.99% | 行业排名> |
| 2023-12-31 | 55.05% | 6.89% | -4.55% | 69/157 | 51.61% | 百利天恒 | 98.92% | 行业排名> |
| 2023-09-30 | 57.67% | 13.86% | -0.57% | 62/157 | 32.47% | 迈威生物 | 98.93% | 行业排名> |
| 2023-06-30 | 58% | 13.48% | -1.51% | 59/157 | 38.42% | 迈威生物 | 99.59% | 行业排名> |
| 2023-03-31 | 58.89% | 5.84% | 14.35% | 55/157 | 52.97% | 迈威生物 | 99.8% | 行业排名> |
| 2022-12-31 | 51.5% | -6% | 1.67% | 83/157 | 53.83% | 迈威生物 | 99.46% | 行业排名> |
| 2022-09-30 | 50.65% | -7.31% | -0.9% | 76/157 | 5.64% | 迈威生物 | 99.75% | 行业排名> |
| 2022-06-30 | 51.11% | -11.48% | -8.14% | 81/157 | 20.99% | 迈威生物 | 99.67% | 行业排名> |
| 2022-03-31 | 55.64% | 0.41% | 1.55% | 67/157 | 54.39% | 迈威生物 | 99.44% | 行业排名> |
| 2021-12-31 | 54.79% | -2.92% | 0.25% | 76/157 | 55.2% | 迈威生物 | 98.57% | 行业排名> |
| 2021-09-30 | 54.65% | -2.83% | -5.35% | 65/157 | 46.77% | 首药控股 | 99.93% | 行业排名> |
| 2021-06-30 | 57.74% | 2.99% | 4.2% | 64/157 | 47.23% | 艾力斯 | 99.41% | 行业排名> |
| 2021-03-31 | 55.41% | 2.48% | -1.81% | 62/157 | 54.13% | 艾力斯 | 98.7% | 行业排名> |
| 2020-12-31 | 56.43% | 8.98% | 0.34% | 65/157 | -148.64% | 艾力斯 | 99.4% | 行业排名> |
| 2020-09-30 | 56.24% | 6.87% | 0.31% | 58/157 | 56.43% | 首药控股 | 99.94% | 行业排名> |
| 2020-06-30 | 56.06% | 9.3% | 3.69% | 58/157 | 54.17% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-03-31 | 54.07% | 9.62% | 4.42% | 54/157 | 55.17% | 微芯生物 | 95.14% | 行业排名> |
| 2019-12-31 | 51.78% | 15.97% | -1.61% | 70/157 | -1242.15% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-09-30 | 52.63% | 19.85% | 2.6% | 56/157 | 55.23% | 微芯生物 | 95.81% | 行业排名> |
| 2019-06-30 | 51.29% | 16.47% | 4% | 62/157 | 55.21% | 微芯生物 | 96.09% | 行业排名> |
| 2019-03-31 | 49.32% | 10.26% | 10.46% | 56/157 | 51.07% | 微芯生物 | 96.11% | 行业排名> |
| 2018-12-31 | 44.65% | -26.07% | 1.68% | 82/157 | -211.97% | 微芯生物 | 95.5% | 行业排名> |
| 2018-09-30 | 43.91% | -27.58% | -0.29% | 63/157 | 54.14% | 微芯生物 | 96.27% | 行业排名> |
| 2018-06-30 | 44.04% | -30.4% | -1.55% | 64/157 | 53.53% | 贝达药业 | 95.47% | 行业排名> |
| 2018-03-31 | 44.73% | -22.59% | -25.94% | 62/157 | 54.16% | 贝达药业 | 95.51% | 行业排名> |
| 2017-12-31 | 60.4% | 9.11% | -0.38% | 41/157 | 52.55% | 贝达药业 | 95.54% | 行业排名> |
| 2017-09-30 | 60.63% | 2% | -4.18% | 28/157 | 49.09% | 贝达药业 | 95.74% | 行业排名> |
| 2017-06-30 | 63.28% | 2% | 9.51% | 25/157 | 47.91% | 退市金泰 | 96.19% | 行业排名> |
| 2017-03-31 | 57.78% | 14.08% | 4.37% | 27/157 | 46.94% | 贝达药业 | 95.81% | 行业排名> |
| 2016-12-31 | 55.36% | 7.26% | 7.26% | 38/157 | 48.46% | 退市金泰 | 95.93% | 行业排名> |